公开(公告)号：WO2023091968A1

公开(公告)日：2023-05-25

申请号：PCT/US2022/079987

申请日：2022-11-16

Applicant: DISC MEDICINE, INC. ,  ABBVIE DEUTSCHLAND GMBH & CO. KG ,  ABBVIE INC.

Inventor： MACDONALD, Brian ,  QUISEL, John ,  SAVAGE, Will ,  YANG, Hua ,  YU, Jonathan ,  WU, Min ,  BECONI, Maria ,  PEREZ, Jennifer, M. ,  MUELLER, Bernhard ,  POPP, Andreas

IPC: A61P7/06 ,  C07K16/22 ,  C07K16/28 ,  A61K39/395 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76

Abstract: Aspects of the application provide hemojuvelin antagonists and methods of using the same in treating anemias of kidney disease and conditions associated with these anemias. Methods provided in the application relate to treatment of a subject having an anemia associated with chronic kidney disease and/or kidney disease in a subject that has a level of glomerular filtration rate lower than one or more thresholds.

公开(公告)号：WO2023086495A1

公开(公告)日：2023-05-19

申请号：PCT/US2022/049581

申请日：2022-11-10

Applicant: CALICO LIFE SCIENCES LLC ,  ABBVIE INC.

Inventor： BOGDAN, Andrew ,  ECONOMOU, Christos ,  FROST, Jennifer M. ,  KYM, Philip R. ,  SCHOLZ, Spencer O. ,  XIONG, Zhaoming

IPC: C07D417/04 ,  C07D417/14 ,  A61K31/433

Abstract: The present invention provides for compounds of Formula (I) wherein R1, has any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of non-small cell lung cancer.

公开(公告)号：WO2023077094A1

公开(公告)日：2023-05-04

申请号：PCT/US2022/078922

申请日：2022-10-28

Applicant: ABBVIE INC. ,  ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED ,  REKEDA, Ludmyla ,  BUDUR, Kumar ,  EARLEY, Willie

Inventor： REKEDA, Ludmyla ,  BUDUR, Kumar ,  EARLEY, Willie

IPC: A61K31/495 ,  A61P25/24 ,  C07D295/033 ,  A61P25/00

Abstract: The present disclosure provides methods for the treatment of major depressive disorder (MDD) by administering cariprazine or a pharmaceutically acceptable salt thereof, as an adjunct to antidepressant therapy in the treatment of subjects with major depressive disorder. The administration of cariprazine achieves statistically significant change from baseline to Week 6 in the Montgomery Asberg Depression Rating Scale (MADRS) total score.

公开(公告)号：WO2023019166A1

公开(公告)日：2023-02-16

申请号：PCT/US2022/074758

申请日：2022-08-10

Applicant: CALICO LIFE SCIENCES LLC ,  ABBVIE INC.

Inventor： VEITS, Gesine Kerstin ,  FITZGERALD, Mark E. ,  HIRD, Alexander W. ,  HENDERSON, James A. ,  VORA, Harit U. ,  SWEIS, Ramzi F. ,  KORT, Michael E. ,  MATULENKO, Mark

IPC: C07D409/14 ,  A61P35/00 ,  A61K31/454

Abstract: Provided herein are compounds, compositions, and methods useful for degrading protein tyrosine phosphatase, e.g., protein tyrosine phosphatase non-receptor type 2 (PTPN2) and/or protein tyrosine phosphatase non-receptor type 1 (PTPN1), and for treating related diseases favorably responsive to PTPN1 or PTPN2 inhibitor treatment, e.g., a cancer or a metabolic disease.

公开(公告)号：WO2023018643A1

公开(公告)日：2023-02-16

申请号：PCT/US2022/039689

申请日：2022-08-08

Applicant: ABBVIE INC.

Inventor： CUSACK, Kevin, Patrick ,  HOEMANN, Michael, Zeller ,  KINSMAN, David, Andrew ,  OSMAN, Sami ,  STAMBULI, James, Patrick ,  ARGIRIADI, Maria, Anastasia ,  O'REILLY, Ciaran ,  DEXTER, Hannah ,  FORDYCE, Euan ,  ST. GALLAY, Steve

IPC: C07D401/06 ,  C07D405/06 ,  C07D413/06 ,  C07D417/06 ,  A61K31/455 ,  A61P29/00

Abstract: Provided herein are compounds of Formula (I) and pharmaceutically acceptable salts thereof, useful as RIPK1 inhibitors, and pharmaceutical compositions comprising same. Further provided are methods of use and preparation. (I)

公开(公告)号：WO2022240786A1

公开(公告)日：2022-11-17

申请号：PCT/US2022/028429

申请日：2022-05-10

Applicant: ABBVIE INC.

Inventor： HAYSLIP, John ,  KYE, Steve, H. ,  AINSWORTH, William, B.

IPC: A61K31/167 ,  A61K31/18 ,  A61K31/337 ,  A61K31/635 ,  A61K31/706 ,  A61P35/00

Abstract: The invention described herein relates to therapeutic dosing regimens comprising administering venetoclax in combination with azacitidine for treating myelodysplastic syndromes (MDS).

公开(公告)号：WO2022232834A1

公开(公告)日：2022-11-03

申请号：PCT/US2022/072008

申请日：2022-04-29

Applicant: ABBVIE INC.

Inventor： PHILLIPS, Andrew C. ,  REILLY, Regina M. ,  DOHERTY, George A. ,  JI, Cheng ,  BRUNCKO, Milan ,  BOGHAERT, Erwin R. ,  ANDERSON, Mark

IPC: C07K16/28 ,  A61K47/68 ,  C07D491/22 ,  C07D317/44 ,  C07D317/70

Abstract: The present disclosure provides c-Met antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

公开(公告)号：WO2022150472A1

公开(公告)日：2022-07-14

申请号：PCT/US2022/011432

申请日：2022-01-06

Applicant: ABBVIE INC. ,  ABBVIE DEUTSCHLAND GMBH & CO KG

Inventor： WALLACE, Kori ,  KALABIC, Jasmina ,  HEAP, Graham, A. ,  LIAO, Xiaomei ,  HUANG, Bidan ,  NEIMARK, Ezequiel ,  SONG, Alexandra, P. ,  ROBINSON, Anne, M.

IPC: C07K16/24 ,  A61P1/00 ,  A61K39/395

Abstract: The present disclosure relates to methods of treating Crohn's disease or inducing remission of Crohn's disease in a subject. The present disclosure also relates to methods of treating ulcerative colitis or inducing remission of ulcerative colitis in a subject.

公开(公告)号：WO2022132997A1

公开(公告)日：2022-06-23

申请号：PCT/US2021/063660

申请日：2021-12-16

Applicant: ABBVIE INC.

Inventor： DEGOEY, David A. ,  DEANDA, JR., Felix ,  DOMBROWSKI, Amanda W. ,  DUBOVYK, Igor ,  GRESZLER, Stephen N. ,  KHRAKOVSKY, Dimitri ,  LEE, Chih-Hung ,  NEWTON, James N. ,  NOEY, Elizabeth L. ,  OKANO, Akinori ,  SIPPY, Kevin B. ,  SOUERS, Andrew J. ,  WANG, Longcheng ,  WILSON, Noel S. ,  ZABLOCKI, Jeffery A.

IPC: A61K31/4162 ,  A61K31/437 ,  C07D471/04 ,  A61P35/00 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention provides for compounds of formula (I); wherein A, R1, R2, R4, W, m, and n have any of the values defined herein, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of CLL and/or SLL.

公开(公告)号：WO2022040896A1

公开(公告)日：2022-03-03

申请号：PCT/CN2020/110971

申请日：2020-08-25

Applicant: ABBVIE INC. ,  ABBVIE PHARMACEUTICAL TRADING (SHANGHAI) CO., LTD.

Inventor： QIU, Yihong ,  ZHOU, Deliang ,  SHEBLEY, Mohamad ,  NG, Wing-Keung,Juki ,  MOHAMED, Ahmed Nader ,  HAN, Jian-Hwa ,  METZGER, David ,  RUGGLES, Alexander ,  ZU, Hui ,  SHAO, Xi ,  GONG, Yuchuan ,  CHEN, Yisheng ,  GONG, Jian ,  LI, Min

IPC: A61K9/48 ,  A61K9/20 ,  A61K31/513 ,  A61K31/565 ,  A61K31/567 ,  A61P15/00

Abstract: A multi-drug delivery system includes a first capsule including a first capsule body that includes a first interior, and a first tablet and a second tablet within the first interior. The first tablet includes a first drug, and the second tablet includes at least a second drug different from the first drug. The first tablet and the second tablet are configured for simultaneous release upon dissolution of the first capsule body within a patient. The system also includes a second capsule including a second capsule body that includes a second interior, and a third tablet within the second interior. The third tablet includes the first drug.